• Ion Opticks

IonOpticks awarded City of Melbourne Business Expansion Grant

Updated: Nov 30, 2018

IonOpticks, a medical research technology company backed by The Walter and Eliza Hall Institute of Medical Research is a proud recipient of a 2018 City of Melbourne Small Business grant.


The expansion grant will be used to scale production capability and capacity for the manufacture of their innovative nano capillary columns.


IonOpticks’ columns are used by cutting edge scientists worldwide for biological and medical research, allowing scientists to gain over 25 per cent more data from their samples compared to existing commercially available solutions.


With the support of the City of Melbourne, IonOpticks will procure vital equipment that will be used to enhance its technical capabilities and streamline the manufacture of first-class laboratory consumables.


IonOpticks thank the City of Melbourne for their generous contribution, and look forward to a continued and fruitful partnership to deliver next generation solutions to the global discovery science community.


Read the City of Melbourne media release here


Learn more about the City of Melbourne's Small Business Grants program here


Please contact selima@ionopticks.com for more information.


(L-R) Dr Jarrod Sandow, Selima Webb, Dr Andrew Webb, Dr Giuseppe Infusini

IonOpticks is an innovative Australian company, based in Parkville, Victoria, that develops, manufactures and distributes advanced proteomics tools. Our aim is to provide innovative solutions for the global proteomics research community that will enable scientists and clinicians to discover more from their samples, accelerating advances in biological and medical research.


We specialise in high-performance chromatography columns for analytical applications in liquid chromatography with mass spectrometry (LC-MS) and high-end proteomics. We manufacture our columns using a highly reproducible method that provides a unique ability to enhance the sensitivity of mass spectrometry sample analysis.


234 views